en
Scientific article
Open access
English

Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir

Published inAntimicrobial agents and chemotherapy, vol. 65, no. 6, p. e00274-21
Publication date2021-05-18
First online date2021-05-18
Abstract

We sought in this case-control retrospective study to compare posaconazole and isavuconazole (PCZ and IVC, respectively) plasma trough concentration (Ctrough) levels in high-risk allogeneic hematopoietic cell transplant (HCT) recipients who received letermovir (LET) or not. PCZ/IVCCtroughlevels were not found to be significantly different between cases and controls, as they were 1.31 mg/liter (median) (interquartile range [IQR], 0.90) versus 1.36 mg/liter (IQR, 1.16) (P = 0.31) and 3.20 mg/liter (IQR, 2.40) versus 2.35 mg/liter (IQR, 1.50) (P = 0.17), respectively. In conclusion, we observed PCZ/IVCCtroughlevels within the expected range and no significant effect of LET coadministration.

eng
Keywords
  • Allogeneic hematopoietic cell transplant recipients
  • Isavuconazole
  • Letermovir
  • Posaconazole
  • Therapeutic drug monitoring
  • Acetates
  • Antifungal Agents / therapeutic use
  • Hematopoietic Stem Cell Transplantation
  • Nitriles
  • Pyridines
  • Quinazolines
  • Retrospective Studies
  • Triazoles
Citation (ISO format)
TERRIER, Jean et al. Clinical and Pharmacological Considerations for Concomitant Administration of Posaconazole and Isavuconazole with Letermovir. In: Antimicrobial agents and chemotherapy, 2021, vol. 65, n° 6, p. e00274–21. doi: 10.1128/AAC.00274-21
Main files (1)
Article (Published version)
accessLevelPublic
Secondary files (1)
Identifiers
ISSN of the journal0066-4804
145views
206downloads

Technical informations

Creation10/21/2021 8:14:00 AM
First validation10/21/2021 8:14:00 AM
Update time03/16/2023 2:41:39 AM
Status update03/16/2023 2:41:38 AM
Last indexation05/06/2024 9:58:51 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack